[en] Proteasome activity is frequently enhanced in cancer to accelerate metastasis and tumorigenesis. REGγ, a proteasome activator known to promote p53/p21/p16 degradation, is often overexpressed in cancer cells. Here we show that p53/TGF-β signalling inhibits the REGγ–20S proteasome pathway by repressing REGγ expression. Smad3 and p53 interact on the REGγ promoter via the p53RE/SBE region. Conversely, mutant p53 binds to the REGγ promoter and recruits p300. Importantly, mutant p53 prevents Smad3/N-CoR complex formation on the REGγ promoter, which enhances the activity of the REGγ–20S proteasome pathway and contributes to mutant p53 gain of function. Depletion of REGγ alters the cellular response to p53/TGF-β signalling in drug resistance, proliferation, cell cycle progression and proteasome activity. Moreover, p53 mutations show a positive correlation with REGγ expression in cancer samples. These findings suggest that targeting REGγ–20S proteasome for cancer therapy may be applicable to human tumours with abnormal p53/Smad protein status. Furthermore, this study demonstrates a link between p53/TGF-β signalling and the REGγ–20S proteasome pathway, and provides insight into the REGγ/p53 feedback loop.
Research Center/Unit :
Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Ali, Amjad ; Université de Liège > Département de pharmacie > Chimie médicale
Wang, Zhuo; Institute of Biomedical Sciences, School of Life Sciences, > Shanghai Key Laboratory of Regulatory Biology, > East China Normal University, 500 Dongchuan Road, Shanghai 200241, China > 1
Fu, Junjiang; Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China
Ma, C. P., Slaughter, C. A. & DeMartino, G. N. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J. Biol. Chem. 267, 10515-10523 (1992).
Dubiel, W., Pratt, G., Ferrell, K. & Rechsteiner, M. Purification of an 11 S regulator of the multicatalytic protease. J. Biol. Chem. 267, 22369-22377 (1992).
Li, X. et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 124, 381-392 (2006).
Chen, X., Barton, L. F., Chi, Y., Clurman, B. E. & Roberts, J. M. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol. Cell 26, 843-852 (2007).
Li, X. et al. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol. Cell 26, 831-842 (2007).
Zhang, Z. & Zhang, R. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J. 27, 852-864 (2008).
Liu, J. et al. REGgamma modulates p53 activity by regulating its cellular localization. J. Cell. Sci. 123, 4076-4084 (2010).
Barton, L. F. et al. Immune defects in 28-kDa proteasome activator gamma-deficient mice. J. Immunol. 172, 3948-3954 (2004).
Murata, S. et al. Growth retardation in mice lacking the proteasome activator PA28gamma. J. Biol. Chem. 274, 38211-38215 (1999).
Okamura, T. et al. Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. J. Clin. Endocrinol. Metab. 88, 1374-1383 (2003).
Wang, X. et al. REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell. Med. Oncol. 28, 31-41 (2011).
Zhang, M., Gan, L. & Ren, G. S. REGgamma is a strong candidate for the regulation of cell cycle, proliferation and the invasion by poorly differentiated thyroid carcinoma cells. Braz. J. Med. Biol. Res. 45, 459-465 (2012).
Roessler, M. et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics 5, 2092-2101 (2006).
He, J. et al. REGgamma is associated with multiple oncogenic pathways in human cancers. BMC Cancer 12, 75 (2012).
Vousden, K. H. & Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604 (2002).
Vousden, K. H. & Prives, C. P53 and prognosis: new insights and further complexity. Cell 120, 7-10 (2005).
Harris, S. L. & Levine, A. J. The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908 (2005).
Bierie, B. & Moses, H. L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506-520 (2006).
Massague, J. TGF-beta signal transduction. Annu. Rev. Biochem. 67, 753-791 (1998).
Derynck, R., Akhurst, R. J. & Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129 (2001).
Massague, J. TGFbeta in cancer. Cell 134, 215-230 (2008).
Akhurst, R. J. & Derynck, R. TGF-beta signaling in cancer - a double-edged sword. Trends Cell. Biol. 11, S44-S51 (2001).
Massague, J. & Gomis, R. R. The logic of TGFbeta signaling. FEBS Lett. 580, 2811-2820 (2006).
Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 3, 807-821 (2003).
Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584 (2003).
Shi, Y. & Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
Levy, L. & Hill, C. S. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41-58 (2006).
Cordenonsi, M. et al. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 113, 301-314 (2003).
Atfi, A. & Baron, R. p53 brings a new twist to the Smad signaling network. Sci. Signal. 1, pe33 (2008).
Brosh, R. & Rotter, V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9, 701-713 (2009).
Loehberg, C. R. et al. Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res. 67, 12026-12033 (2007).
Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872 (2004).
Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 (2004).
Gualberto, A., Aldape, K., Kozakiewicz, K. & Tlsty, T. D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl Acad. Sci. USA 95, 5166-5171 (1998).
Murphy, K. L., Dennis, A. P. & Rosen, J. M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J. 14, 2291-2302 (2000).
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T. & Prives, C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell Biol. 21, 1874-1887 (2001).
Strano, S. et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275, 29503-29512 (2000).
Lin, J., Teresky, A. K. & Levine, A. J. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10, 2387-2390 (1995).
Matas, D. et al. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J. 20, 4163-4172 (2001).
Kim, E. & Deppert, W. Transcriptional activities of mutant p53: when mutations are more than a loss. J. Cell. Biochem. 93, 878-886 (2004).
Weisz, L., Oren, M. & Rotter, V. Transcription regulation by mutant p53. Oncogene 26, 2202-2211 (2007).
Li, X., Chuang, C. K., Mao, C. A., Angerer, L. M. & Klein, W. H. Two Otx proteins generated from multiple transcripts of a single gene in Strongylocentrotus purpuratus. Dev. Biol. 187, 253-266 (1997).
el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. & Vogelstein, B. Definition of a consensus binding site for p53. Nat. Genet. 1, 45-49 (1992).
Menendez, D., Inga, A. & Resnick, M. A. The expanding universe of p53 targets. Nat. Rev. Cancer 9, 724-737 (2009).
Murphy, M. et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13, 2490-2501 (1999).
Jang, H., Choi, S. Y., Cho, E. J. & Youn, H. D. Cabin1 restrains p53 activity on chromatin. Nat. Struct. Mol. Biol. 16, 910-915 (2009).
Massague, J., Seoane, J. & Wotton, D. Smad transcription factors. Genes Dev. 19, 2783-2810 (2005).
Elston, R. & Inman, G. J. Crosstalk between p53 and TGF-beta Signalling. J. Signal Transduct. 2012 pp 294097 (2012).
Cordenonsi, M. et al. Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science 315, 840-843 (2007).
Zalcenstein, A. et al. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 25, 359-369 (2006).
Weisz, L. et al. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res. 64, 8318-8327 (2004).
Zalcenstein, A. et al. Mutant p53 gain of function: repression of CD95 (Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22, 5667-5676 (2003).
Yan, W. & Chen, X. Identification of GRO1 as a critical determinant for mutant p53 gain of function. J. Biol. Chem. 284, 12178-12187 (2009).
Yan, W., Liu, G., Scoumanne, A. & Chen, X. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res. 68, 6789-6796 (2008).
Fontemaggi, G. et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat. Struct. Mol. Biol. 16, 1086-1093 (2009).
Acin, S., Li, Z., Mejia, O., Roop, D. R., El-Naggar, A. K. & Caulin, C. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J. Pathol. 225, 479-489 (2011).
Kalo, E. et al. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Mol. Cell Biol. 27, 8228-8242 (2007).
